Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1634012 | 0.85 | TP53 (0.30) | — | |
| SCHEMBL5268352 | 0.78 | — | — | |
| SCHEMBL152158 | 0.75 | — | — | |
| SCHEMBL6748966 | 0.73 | — | — | |
| SCHEMBL11237022 | 0.72 | TP53 (0.50) | CYP2C19 | |
| SCHEMBL6744443 | 0.71 | — | — | |
| SCHEMBL3346640 | 0.71 | ALDH1A1 (0.33) | LMNAALDH1A1 | |
| SCHEMBL2231830 | 0.71 | ALDH1A1 (0.33) | LMNAALDH1A1 | |
| SCHEMBL10860471 | 0.69 | — | — | |
| SCHEMBL11786285 | 0.69 | ALDH1A1 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699979-B2 | PREPARED VIA A STEREOSPECIFIC SN2 NUCLEOPHILIC ATTACK OF A PHOSPHODIESTER, OR PHOSPHOROTHIOATE, ON THE 3' POSITION OF A XYLONUCLEOTIDE; USEFUL IN ANTISENSE OR PROBE TECHNOLOGY | ISIS PHARMACEUTICALS, INC. | 2004-03-02 | — | — | US | disclosed |
| US-6500945-B2 | BIOSYNTHESIS; STEREOSPECIFIC | ISIS PHARMACEUTICALS, INC. | 2002-12-31 | — | — | US | disclosed |
| US-20020137921-A1 | Oligonucleotides having chiral phosphorus linkages | COOK PHILLIP DAN (US) | 2002-09-26 | — | — | US | disclosed |
| EP-0655088-B1 | OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES | ISIS PHARMACEUTICALS INC (US) | 2002-07-24 | — | — | EP | disclosed |
| US-20010008936-A1 | Oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS, INC. | 2001-07-19 | — | — | US | disclosed |
| US-6239265-B1 | FOR RESEARCH AND DIAGNOSIS | ISIS PHARMACEUTICALS, INC. | 2001-05-29 | — | — | US | disclosed |
| US-5852188-A | Oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| US-5521302-A | NUCLEOPHILIC REACTION OF PHOSPHATE GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1996-05-28 | — | — | US | disclosed |
| EP-0655088-A1 | OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5212295-A | Monomers for preparation of oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS (US) | 1993-05-18 | — | — | US | disclosed |
| WO-1993008296-A1 | OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137921-A1 | Oligonucleotides having chiral phosphorus linkages | RNGTT, PNP, PSPH | CYP2C19 4561/4885LMNA 3960/4885ALDH1A1 4784/4885 |
| US-20010008936-A1 | Oligonucleotides having chiral phosphorus linkages | RNGTT, PNP, PSPH | CYP2C19 4561/4885LMNA 3960/4885ALDH1A1 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.